Study guide
16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration
Key Takeaways Explain This Topic AI
Standardized psychosocial screening using validated instruments is an AACVPR-mandated core component required at both program enrollment (baseline intake) and graduation (exit evaluation) for all Phase II cardiac rehabilitation participants.
The Patient Health Questionnaire-9 (PHQ-9) categorizes depression severity across 9 DSM-based items (0–27 total): 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, and 20–27 severe; a score of 10 or greater represents the clinical threshold warranting clinical evaluation and referral.
PHQ-9 Question 9 screens specifically for passive or active suicidal ideation; any score greater than 0 is a mandatory clinical red flag requiring immediate safety evaluation before the patient departs the facility, regardless of total instrument score.
The Generalized Anxiety Disorder-7 (GAD-7) instrument classifies anxiety symptoms (0–21 total): 0–4 minimal, 5–9 mild, 10–14 moderate, and 15–21 severe; a score of 10 or higher serves as the validated cutoff indicating clinically meaningful generalized anxiety, panic disorder, or post-traumatic stress symptoms.
Administering identical instruments at program completion serves as a vital AACVPR clinical outcome measure to document therapeutic progress, evaluate intervention efficacy, and ensure seamless transition of care for patients with persistent distress.
Last updated: September 2026
16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration
Note
AACVPR Core Quality Measure : Psychosocial assessment is not an elective or ancillary service in secondary prevention. The AACVPR Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs (6th Edition) and performance standards from the American College of Cardiology (ACC) and American Heart Association (AHA) mandate that all participating patients undergo standardized, validated psychosocial screening at baseline entry (intake) and upon program completion (exit) . Results must be incorporated into the patient's Individualized Treatment Plan (ITP) within 30 days of enrollment.
Cardiovascular clinicians cannot reliably detect clinical depression or anxiety through unstandardized casual conversation or subjective impression alone. Up to 50% of depressed cardiac patients are missed during routine medical encounters when structured screening is omitted. Validated psychometric instruments provide standardized, reproducible, and quantifiable data that establish baseline risk, stratify clinical severity, trigger mandatory crisis workflows, and measure longitudinal therapeutic response.
Clinical & Regulatory Mandates for Psychosocial Screening
The mandate for standardized psychosocial screening in cardiac rehabilitation rests upon both clinical necessity and regulatory standards:
AACVPR Program Certification : To achieve and maintain AACVPR program certification, cardiac rehabilitation facilities must document baseline and exit psychosocial screening in 100% of enrolled patients or record explicit clinical justification for omissions.
CMS Individualized Treatment Plan (ITP) : The Centers for Medicare & Medicaid Services (CMS) mandates that an ITP be established for every Phase II participant, signed by the Medical Director, and updated at least every 30 calendar days. Objective psychosocial assessment is one of the four foundational core outcome domains (alongside exercise capacity, cardiovascular risk factors, and nutritional status).
Joint Commission Standards : Behavioral health screening aligns with Joint Commission National Patient Safety Goals regarding the identification of depression and suicide risk in ambulatory and acute healthcare settings.
Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 (PHQ-9) is the premier, gold-standard screening instrument utilized across cardiovascular medicine. It is a 9-item, patient-completed diagnostic and severity-grading tool that maps directly onto the 9 diagnostic criteria for Major Depressive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
Administration and Scoring Mechanics
Patients rate the frequency of each symptom experienced over the preceding 2 weeks on a 4-point Likert scale:
- 0 = Not at all
- 1 = Several days
- 2 = More than half the days
- 3 = Nearly every day
The total score is calculated by summing all 9 responses, yielding a continuous score from 0 to 27 .
- Clinical Severity Categories and Cutoffs [ 0 - 4 ] [ 5 - 9 ] [ 10 - 14 ] [ 15 - 19 ] [ 20 - 27 ]
- Minimal Mild Moderate Moderately Severe Severe
- (Education) (Watchful Wait) (Referral / ITP) (Active Treatment) (Urgent Escalation)
- ▲
- │
- Clinical Cutoff Threshold (≥10)
0 to 4 (Minimal / None) : Normal psychological adjustment; continue standard secondary prevention psychoeducation.
5 to 9 (Mild Depression) : Mild depressive symptoms. Management includes watchful waiting, repetition of screening at mid-program (session 18), and lifestyle stress coaching.
10 to 14 (Moderate Depression) : The validated clinical cutoff (Score ≥ 10) . A score of 10 exhibits a sensitivity of 88% and specificity of 88% for major depression. Requires clinical discussion, formulation of specific behavioral goals in the ITP, and consultation with the patient's primary care provider or cardiologist regarding psychological referral.
15 to 19 (Moderately Severe Depression) : High likelihood of major depressive disorder; warrants active referral for psychotherapy (CBT) and/or evaluation for antidepressant pharmacotherapy.
20 to 27 (Severe Depression) : Severe clinical depression; urgent psychiatric evaluation and intensive collaborative management are required.
The Critical Red-Flag: Question 9 (Suicidal Ideation)
Question 9 asks whether the patient has had: "Thoughts that you would be better off dead, or of hurting yourself in some way."
Mandatory Safety Rule : Question 9 is an independent, non-negotiable safety screen. Any score of 1, 2, or 3 triggers an immediate clinical safety evaluation , regardless of whether the total PHQ-9 score is low (e.g., a patient scoring a total of 4 who marks '1' on Question 9 must be assessed for suicide risk before leaving the facility).
Never Defer : A positive response to Question 9 can never be deferred to an upcoming multidisciplinary team meeting or routine physician notification letter.
Generalized Anxiety Disorder-7 (GAD-7)
Anxiety in cardiac populations frequently presents as debilitating health hypervigilance, somatic preoccupation, and fear of exercise-induced death. The Generalized Anxiety Disorder-7 (GAD-7) is a 7-item instrument that assesses generalized anxiety symptoms over the past 2 weeks.
Scoring Mechanics and Severity Stratification
Each item is scored from 0 (Not at all) to 3 (Nearly every day), generating a total score ranging from 0 to 21 :
0 to 4 (Minimal Anxiety) : Standard exercise progression and supportive education.
5 to 9 (Mild Anxiety) : Provide reassurance, educate on exercise physiology, and teach basic diaphragmatic relaxation techniques.
10 to 14 (Moderate Anxiety) : The validated clinical cutoff (Score ≥ 10) . Sensitivity is 89% and specificity is 82% for generalized anxiety disorder; strongly identifies coexisting panic disorder and social phobia. Warrants behavioral therapy referral and targeted cognitive reframing.
15 to 21 (Severe Anxiety) : Marked autonomic arousal, severe somatic magnification, and exercise phobia. Active mental health referral and collaborative medical consultation are indicated.
Psychometric Specifications and Action Protocols
Instrument Items & Scoring Clinical Cutoff (Action Trigger) Key Strengths Somatic Confounders & Caveats
PHQ-9 9 items (0–27 scale) Score ≥ 10 : Clinical depression evaluation; Q9 > 0 : Immediate suicide safety screen Directly mirrors DSM-5 MDD criteria; sensitive to change over time Sleep, fatigue, and appetite items may reflect cardiac deconditioning or heart failure
GAD-7 7 items (0–21 scale) Score ≥ 10 : Clinical anxiety evaluation and behavioral referral Excellent sensitivity for GAD, panic disorder, and social anxiety Palpitations, tremors, and restlessness can overlap with beta-blocker withdrawal or arrhythmias
PHQ-2 2 items (0–6 scale) Score ≥ 3 : Mandatory administration of full PHQ-9 Ultra-rapid initial screen (depressed mood and anhedonia) Does not assess suicidal ideation; cannot measure treatment response over time
- Administration Logistics & Navigating Somatic Overlap
- Baseline Intake Administration
Setting : The screening should occur in a private, quiet clinical interview area during the patient's initial nursing or physiological intake assessment, prior to exercise orientation.
Methodology : Self-administered on paper or tablet, or administered verbally by the CCRP clinician if the patient possesses visual impairments or limited health literacy. Clinicians must explain that assessing emotional wellness is a routine, universal component of comprehensive cardiac care to remove stigma.
The Challenge of Somatic Symptom Overlap
Cardiac patients frequently endorse physical symptoms that are shared between cardiopulmonary pathophysiology and psychological disorders:
Shared Vegetative Symptoms : Fatigue, insomnia, reduced physical stamina, altered appetite, and psychomotor slowing can arise directly from congestive heart failure, postoperative recovery, beta-blocker therapy, or major depression.
Clinical Best Practice : CCRP clinicians should not arbitrarily discount somatic symptoms. When a patient endorses profound fatigue or sleep disruption, clinicians should explore the cognitive-affective items (e.g., anhedonia, feelings of worthlessness, excessive guilt). If cognitive-affective items are elevated alongside somatic items, depressive pathology is confirmed.
Exit Evaluation: Measuring Clinical Outcomes
Timing : Re-administered during the final week of Phase II participation (typically sessions 30 to 36).
Outcome Documentation : Comparing baseline and exit scores provides an objective metric of programmatic success. Successful cardiac rehabilitation typically yields a 30% to 50% reduction in PHQ-9 and GAD-7 scores .
Warm Handoff for Non-Responders : Patients who maintain persistent scores ≥ 10 at exit evaluation must not be discharged without a documented transition plan, including a direct communication to their primary care provider or cardiologist.
Realistic Clinical Scenario: Somatic Overlap and Positive Intake Screening
Clinical Scenario : A 68-year-old male post-NSTEMI with a drug-eluting stent to the right coronary artery presents for Phase II intake. During the baseline survey, his PHQ-9 score is 12 (Moderate Depression), and his GAD-7 score is 11 (Moderate Anxiety). On the PHQ-9, he marked '2' (More than half the days) for sleep disruption, '2' for fatigue, '2' for feeling down or depressed, and '2' for little interest or pleasure in doing things (anhedonia). Question 9 was scored '0' (Not at all). On the GAD-7, he marked '3' for worrying excessively about his heart stopping during exertion.
Clinical Interpretation & Action :
Somatic vs. Affective Differentiation : Although sleep disturbance and fatigue could be secondary to cardiac recovery, the concurrent endorsement of persistent depressed mood and core anhedonia confirms clinically meaningful depressive distress.
Safety Confirmation : Question 9 is negative (0), confirming that acute suicidal crisis protocol is not required.
ITP Formulation : The clinician establishes measurable behavioral goals: (1) participate in twice-weekly group stress management classes, (2) introduce diaphragmatic breathing to manage exertional anxiety, and (3) achieve a target reduction of PHQ-9 and GAD-7 scores to <10 by program completion.
Care Coordination : A copy of the intake assessment and summary note is transmitted to the referring cardiologist, alerting them to the baseline score of 12 and outlining the rehab program's supportive behavioral interventions.